RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping ...

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...

Johnson & Johnson is one of the largest pharmaceutical stocks by market cap. Pfizer's dividend offers a hefty yield. Revenue ...

BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...

Analysts highlight Pfizer and Medical Properties Trust (MPT) as attractive high-yield dividend stocks for April despite market volatility and economic uncertainty. Pfizer’s 6.4% forward yield is ...

Dividend stocks are a great way for investors to generate passive income that can be more reliable and predictable than investing in stocks for pure appreciation. While there are no guarantees in the ...

The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...